Insider sale
NEWAMSTERDAM PHARMA CO N.V.
$10.25M
267.43K shares
What this filing means
BAIN CAPITAL LIFE SCIENCES FUND II, L.P. plans to sell 267.43K shares of NEWAMSTERDAM PHARMA CO N.V. valued at approximately $10.25M. Form 144 is a notice of intent to sell restricted or control securities — not a mandatory transaction. This filing provides advance warning of potential selling pressure.
Filed: 12/2/2025ACC: 0001193125-25-305720
→
10% Owner
Since Dec 2023
267.43K
Shares to sell
$10.25M
Approx. market value
267.43K
Acquired (3 months)
1
Planned
Securities Acquired — Last 3 Months1
Purchase of ordinary shares in the initial public offering of Frazier Lifesciences Acquisition Corporation, which ordinary shares were automatically exchanged on a 1:1 basis for ordinary shares of the Issuer on November 22, 2022.
Cash
12/11/2020
267.43KTotal acquired267.43K
| Acquisition Date | Type | Amount Acquired | Gift |
|---|---|---|---|
12/11/2020 | Purchase of ordinary shares in the initial public offering of Frazier Lifesciences Acquisition Corporation, which ordinary shares were automatically exchanged on a 1:1 basis for ordinary shares of the Issuer on November 22, 2022. Cash | 267.43K | — |
| Total | 267.43K | ||
Planned & Completed Dispositions1
NasdaqPlanned
Units to sell
267.43K
Market value
$10.25M
12/2/2025
Total
Units
267.43K
Value
$10.25M
| Date | Units to Sell | Approx. Market Value | Exchange | Status |
|---|---|---|---|---|
12/2/2025 | 267.43K | $10.25M | Nasdaq | Planned |
| Total | 267.43K | $10.25M | ||